Norovirus vaccine developer HilleVax upsizes proposed IPO to $175M
By Val Kennedy, Novovirus vaccine developer HilleVax (HLVX) has upsized its initial public offering to $175M from $100M. The biotech company said in an amended filing on Monday that it now plans to offer 10.3M shares priced between $16 and $18 per share. If priced at the midpoint, the company would raise approximately $175M. In a filing[…]